Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20248041 | 1.00 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ANPEPLAP3 | |
| SCHEMBL15588619 | 1.00 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ANPEPLAP3 | |
| SCHEMBL16374214 | 1.00 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ANPEPLAP3 | |
| SCHEMBL524066 | 1.00 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ANPEPLAP3 | |
| SCHEMBL19813730 | 0.95 | BTN3A1 (0.51) | BTN3A1CYP3A4CYP2C9ANPEPLAP3 | |
| SCHEMBL23992574 | 0.88 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 | |
| SCHEMBL800889 | 0.88 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 | |
| SCHEMBL12870471 | 0.88 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 | |
| SCHEMBL25387275 | 0.88 | BTN3A1 (0.53) | BTN3A1ANPEPLAP3ELANEMEN1 | |
| SCHEMBL31355395 | 0.87 | NPC1 (0.49) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| EP-3303362-B1 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2022-10-19 | — | — | EP | claimed |
| US-10676498-B2 | Processes for the preparation of sofosbuvir and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2020-06-09 | — | — | US | claimed |
| US-20190218243-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2019-07-18 | — | — | US | claimed |
| EP-3303362-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2018-04-11 | — | — | EP | claimed |
| WO-2016196735-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-12-08 | — | — | WO | claimed |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | UNIV EMORY (US) | 2026-02-26 | — | — | US | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | TYMP, DTYMK, TYMS | BTN3A1 1100/4885CYP3A4 4035/4885CYP2C9 4622/4885 |
| US-10676498-B2 | Processes for the preparation of sofosbuvir and intermediates thereof | CYP3A4, EIF2AK2, RTF2 | BTN3A1 4636/4885CYP3A4 1/4885CYP2C9 34/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3738/4885CYP3A4 3811/4885CYP2C9 3971/4885 |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | BTN3A1 3871/4885CYP3A4 373/4885CYP2C9 1163/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | BTN3A1 4840/4885CYP3A4 530/4885CYP2C9 323/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | BTN3A1 4329/4885CYP3A4 2299/4885CYP2C9 1454/4885 |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | DCTD, RNMT, NSUN2 | BTN3A1 4369/4885CYP3A4 1539/4885CYP2C9 654/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | BTN3A1 4516/4885CYP3A4 1190/4885CYP2C9 932/4885 |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | MTAP, PNP, NSUN2 | BTN3A1 4120/4885CYP3A4 1800/4885CYP2C9 1773/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | IRAK2, IRAK3, IRAK1 | BTN3A1 4216/4885CYP3A4 1788/4885CYP2C9 2390/4885 |
| US-20190218243-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | EIF2AK2, CYP3A4, RTF2 | BTN3A1 4612/4885CYP3A4 2/4885CYP2C9 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.